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Identity 
Note: Trisomy 12 is the most common cytogenetic 
change in chronic lymphocytic leukemia (CLL); 
however, it has also been observed in other subtypes of 
B-cell lymphoproliferative disorders, where it is not 
seldomly a secondary change. 
Clinics and pathology 
Disease 
B-cell chronic lymphocytic leukemia (B-CLL). 
Phenotype/cell stem origin 
virgin CD5+ recirculating B-cell; the classical CLL 
phenotype is CD5+, CD23+, CD22-, CD79a-, FMC7-, 
sIg weak; trisomy 12 is more often observed in CLL 
with morphologically and immunologically atypical 
cells, displaying CD5 negativity or FMC7 positivity 
and strong surface immunoglobulin staining; trisomy 
12 is present in proliferating cells and seems to be 
associated with the absence of mutation of the Ig 
variable region genes. 
Epidemiology 
Trisomy 12 is found in one third of cytogenetically 
abnormal CLLs by conventional karyotype, and in 
about 12-54% of cases when interphase FISH is used. 
Prognosis 
A significant difference comparing the therapy-free 
interval of patients with +12 and patients with other 
anomalies was found; this observation was repeatedly 
confirmed; however an adverse impact of +12 on 
survival could not be demonstrated until the IWCLL 
compiled karyotype and survival data from more than 
400 patients and showed a median survival of 5.4 years 
versus 8.6 years versus 14 years in patients with +12 
versus another single abnormality versus a normal 
karyotype, respectively; the preliminary results on a 
large series of patients analyzed by interphase FISH 
showed that +12 and 14q+ changes are associated with 
shorter survival times, compared to patients with 13q 
abnormalities and normal karyotypes; however 
prospective data are needed to further assess the 
prognostic value of this cytogenetic change. 
Disease 
B-cell non Hogkin's lymphomas, distinct from CLL, 
i.e. prolymphocytic leukemia, hairy cell leukemia, 
splenic lymphoma with villous lymphocytes (SLVL), 
Waldenström's disease, follicular lymphoma, mantle 
cell lymphoma, and diffuse large cell lymphoma. 
Phenotype/cell stem origin 
Lack of specificity for a particular immunophenotype. 
Prognosis 
No data are available concerning the prognostic 
significance of +12, except in one series of mantle cell 
lymphomas in which it was the only single cytogenetic 
parameter associated with poor prognosis. 
Cytogenetics 
Cytogenetics morphological 
Using restriction fragment length polymorphism 
analysis, the extra chromosome 12 has been shown to 
derive from duplication of one chromosome 12,  
with retention of the other homolog rather than from 
triplication of one homolog; trisomy 12 is thought to be 
a secondary change since combined immunological and 
cytogenetic studies showed that it is present in only a 
part of the neoplastic B-cells; cases with partial 
duplication 12q were analyzed by FISH, and a 
"minimal duplicated region" could be defined in 
segment 12q13-12q15. 
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